ContextVision AB (OSTO:COVo)

Q1 2025 ContextVision AB Earnings Call Transcript

May 7, 2025 / 07:00 AM GMT

Release Date Price: kr4.98 (-16.88%)

Transcript

Key Points

Positve

ContextVision AB (LTS:0L8Z) executed a significant partnership agreement with the University of Washington to advance digital organ-specific ultrasound-based biomarkers.
The company expanded its footprint in the image processing chain through ongoing fruitful collaborations with leading OEMs.
Record number of customer meetings and extended contracts with existing accounts were achieved, indicating strong customer engagement.
The company has a strong cash position of 70 million, providing ample room for further investments and shareholder value activities.
Additional partnerships with the University of Waterloo and Inhase Solutions enhance the company's data quality venture, particularly in advanced liver imaging.

Negative

Revenue declined by 24% compared to the previous year's record high quarter, reaching 26.3 million.
The strengthening of the SEK against the US dollar and EUR negatively impacted revenue by 1.8%.
Seasonality and an unfavorable ultrasound customer mix affected sales from some of the largest customers.
Increased investments in data quality and IT led to higher costs and a negative cash flow of 3.7 million.
The company faces short-term market uncertainty and increased volatility, particularly concerning currency fluctuations and tariffs.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

CONTX.OL - ContextVision AB
Q1 2025 ContextVision AB Earnings Call
May 07, 2025 / 07:00AM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Welcome to Context Vision and thank you for joining our Q1 2025 webcast today with Richard Halstrom, our CFO, and myself, Gerald. As usual, we'll give you an update on our business. We'll look into the financials and we'll close with a summary and outlook.

Looking into the 1st quarter.

The first clear highlight, which is also a very important milestone in the journey of the company, is the execution of a partnership agreement with the University of Washington in Seattle, United States. This is to support our journey in delivering and building digital organs specific ultrasound based biomarkers, a clear step forward in our journey towards data quality.

In line with that partnership agreement and to enable clinical

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.